French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

The approval is based on IXCHIQ®’s final pivotal Phase 3 data ... We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and ...

Participants were randomized 2:2:1 to receive either a full dose (licensed IXCHIQ® formulation and ... We also sell both admissions and sponsorship packages for our investment conferences and ...

The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years ... "We think it's based on, you know, the overall data package we've been able to generate, and the ...

The Business Research Company's Ixchiq Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...

Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory ...

The vaccine is manufactured at Valneva's leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ ® 's final pivotal Phase 3 data, published in The Lancet, which ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet, which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated ...

Ixchiq is now the first vaccine approved in the UK to prevent disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older. CHIKV is a mosquito-borne viral disease that ...